CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
101
Frequently Asked Questions
What is Market Cap of Cymabay Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Cymabay Therapeutics Inc market cap is $3.73B.
What is the 52-week high for Cymabay Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Cymabay Therapeutics Inc 52 week high is $32.50 as of April 24, 2024.
What is the 52-week low for Cymabay Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Cymabay Therapeutics Inc 52 week low is $7.26 as of April 24, 2024.
What is Cymabay Therapeutics Inc stock price today?
Cymabay Therapeutics Inc stock price today is $32.48.
What was Cymabay Therapeutics Inc stock price yesterday?
Cymabay Therapeutics Inc stock price yesterday was $32.47.
What is the PE ratio of Cymabay Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Cymabay Therapeutics Inc’s P/E ratio is -32.75.
What is the Price-to-Book ratio of Cymabay Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Cymabay Therapeutics Inc P/B ratio is 12.6544.
What is Cymabay Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Cymabay Therapeutics Inc's EBITDA is -23.73.
What is the 50-day moving average of Cymabay Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Cymabay Therapeutics Inc 50-day moving average is $29.45.
How many employess does Cymabay Therapeutics Inc has?